Karen Dagerman

5.3k total citations · 3 hit papers
17 papers, 3.4k citations indexed

About

Karen Dagerman is a scholar working on Psychiatry and Mental health, Physiology and Philosophy. According to data from OpenAlex, Karen Dagerman has authored 17 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Psychiatry and Mental health, 4 papers in Physiology and 3 papers in Philosophy. Recurrent topics in Karen Dagerman's work include Schizophrenia research and treatment (10 papers), Dementia and Cognitive Impairment Research (9 papers) and Mental Health and Psychiatry (3 papers). Karen Dagerman is often cited by papers focused on Schizophrenia research and treatment (10 papers), Dementia and Cognitive Impairment Research (9 papers) and Mental Health and Psychiatry (3 papers). Karen Dagerman collaborates with scholars based in United States, United Kingdom and Czechia. Karen Dagerman's co-authors include Philip S. Insel, Lon S. Schneider, Lon S. Schneider, Pierre N. Tariot, Barry D. Lebowitz, John Hsiao, David L. Sultzer, Sonia M. Davis, T. Scott Stroup and Jeffrey A. Lieberman and has published in prestigious journals such as New England Journal of Medicine, JAMA and American Journal of Psychiatry.

In The Last Decade

Karen Dagerman

16 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia

2005 1.2k citations Lon S. Schneider, Karen Dagerman et al. JAMA profile →
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease

2006 760 citations Lon S. Schneider, Pierre N. Tariot et al. New England Journal of Medicine profile →
Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials

2006 623 citations Lon S. Schneider, Karen Dagerman et al. American Journal of Geriatric Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Dagerman United States	11	2.4k	581	498	492	484	17	3.4k
Heidi Taipale Finland	38	3.7k 1.5×	837 1.4×	864 1.7×	265 0.5×	407 0.8×	257	5.8k
Kaycee M. Sink United States	31	1.8k 0.8×	888 1.5×	444 0.9×	524 1.1×	1.5k 3.1×	93	5.2k
Joan Vilalta‐Franch Spain	33	1.7k 0.7×	292 0.5×	458 0.9×	705 1.4×	514 1.1×	107	3.0k
Sylvaine Artéro France	30	2.1k 0.9×	511 0.9×	574 1.2×	344 0.7×	839 1.7×	79	4.1k
Beverly N. Jones United States	18	2.4k 1.0×	321 0.6×	281 0.6×	523 1.1×	993 2.1×	23	5.0k
Hanna Kaduszkiewicz Germany	33	1.6k 0.6×	629 1.1×	283 0.6×	982 2.0×	529 1.1×	124	3.8k
Jacqueline Stack United States	28	1.5k 0.6×	349 0.6×	718 1.4×	373 0.8×	421 0.9×	57	4.6k
Jacobo Mintzer United States	40	3.7k 1.5×	529 0.9×	757 1.5×	473 1.0×	1.3k 2.7×	137	6.0k
Jason T. Olin United States	34	2.5k 1.0×	322 0.6×	501 1.0×	431 0.9×	1.3k 2.7×	79	5.1k
Helen C. Kales United States	45	3.6k 1.5×	804 1.4×	1.4k 2.7×	1.7k 3.4×	482 1.0×	170	6.6k

Countries citing papers authored by Karen Dagerman

Since Specialization

Citations

This map shows the geographic impact of Karen Dagerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Dagerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Dagerman more than expected).

Fields of papers citing papers by Karen Dagerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Dagerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Dagerman. The network helps show where Karen Dagerman may publish in the future.

Co-authorship network of co-authors of Karen Dagerman

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Dagerman. A scholar is included among the top collaborators of Karen Dagerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Dagerman. Karen Dagerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Sultzer, David L., John Hsiao, Sonia M. Davis, et al.. (2021). Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. UNC Libraries. 1 indexed citations

Dagerman, Karen, Pierre N. Tariot, David L. Sultzer, et al.. (2020). Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer’s Disease Patients: The CATIE-AD Study. UNC Libraries.

Vigen, Cheryl, Wendy J. Mack, Richard S.E. Keefe, et al.. (2011). Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. American Journal of Psychiatry. 168(8). 831–839. 178 indexed citations

Schneider, Lon S., Cheryl Vigen, Wendy J. Mack, et al.. (2009). O4‐04‐01: Citalopram compared to atypical antipsychotics for Alzheimer patients who did not previously benefit from treatment: The catie‐AD study. Alzheimer s & Dementia. 5(4S_Part_5). 8 indexed citations

Zheng, Ling, Wendy J. Mack, Karen Dagerman, et al.. (2009). Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer’s Disease Patients: The CATIE-AD Study. American Journal of Psychiatry. 166(5). 583–590. 65 indexed citations

Sultzer, David L., Sonia M. Davis, Pierre N. Tariot, et al.. (2008). Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. American Journal of Psychiatry. 165(7). 844–854. 207 indexed citations

Schneider, Lon S., et al.. (2008). O3‐04–08: No secular trend and high variability for ADAS‐cog change among placebo groups from clinical trials. Alzheimer s & Dementia. 4(4S_Part_5). 4 indexed citations

Dagerman, Karen, et al.. (2007). National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimers Disease (CATIE-AD): Baseline Characteristics. Current Alzheimer Research. 4(3). 325–335. 10 indexed citations

Schneider, Lon S., Karen Dagerman, & Philip S. Insel. (2006). Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials. American Journal of Geriatric Psychiatry. 14(3). 191–210. 623 indexed citations breakdown →

10.

Dagerman, Karen, Maryellen C. MacDonald, & Michael W. Harm. (2006). Aging and the Use of Context in Ambiguity Resolution: Complex Changes From Simple Slowing. Cognitive Science. 30(2). 311–345. 43 indexed citations

11.

Schneider, Lon S., Pierre N. Tariot, Karen Dagerman, et al.. (2006). Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. New England Journal of Medicine. 355(15). 1525–1538. 760 indexed citations breakdown →

12.

Schneider, Lon S., Karen Dagerman, & Philip S. Insel. (2006). Atypical Antipsychotic Drugs, Dementia, and Risk of Death—Reply. JAMA. 295(5). 495–495. 1 indexed citations

13.

Schneider, Lon S., Karen Dagerman, & Philip S. Insel. (2005). Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia. JAMA. 294(15). 1934–1934. 1178 indexed citations breakdown →

14.

Schneider, Lon S. & Karen Dagerman. (2003). Psychosis of Alzheimer's disease: clinical characteristics and history. Journal of Psychiatric Research. 38(1). 105–111. 45 indexed citations

15.

Schneider, Lon S., M. Saleem Ismail, Karen Dagerman, et al.. (2003). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial. Schizophrenia Bulletin. 29(1). 57–72. 45 indexed citations

16.

Olin, Jason T., et al.. (2002). Increasing Ethnic Minority Participation in Alzheimer Disease Research. Alzheimer Disease & Associated Disorders. 16. S82–S85. 43 indexed citations

17.

Schneider, Lon S., Pierre N. Tariot, Constantine G. Lyketsos, et al.. (2001). National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal of Geriatric Psychiatry. 9(4). 346–360. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact